Skip to content
OpenCapital
Get started

Gilead Sciences GILD Cash & Equivalents

Cash & Equivalents at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$9.57B-12.0%
Incyte logo
IncyteINCY
$3.98B+104%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$205.19M+238%
Precigen logo
PrecigenPGEN
$7.48M+23.5%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$248.47M+152%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$196.51M+14.5%

Other financials

Income statement

See full
Revenue$7.0B+4.4%
Gross profit$5.5B+7.6%
Operating income$2.6B+15.6%
Net income$2.0B+53.7%
EPS (diluted)$1.61+54.8%

Balance sheet

See full
Total debt$22.2B-11.1%
Total equity$23.5B+22.7%
Total assets$56.3B-0.3%

Cash flow

See full
Operating cash flow$2.5B+44.8%
CapEx$117.0M+12.5%
Free cash flow$2.4B+46.8%

Valuation

See full
Market cap$160.55B+14.2%
Enterprise value$175.09B+9.2%
P/E17.4×-4.9×
P/S5.4×+0.5×

Profitability

See full
Gross margin79.4%+1.1pp
Operating margin34.9%+6.3pp
Net margin31%+10.2pp
FCF margin34.4%+0.1pp

Returns & leverage

See full
Return on equity43.2%+10.7pp
Debt / equity0.9×-0.4×
Current ratio2×+0.6×

Where this comes from

Reported directly by Gilead Sciences in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gilead Sciences's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Gilead Sciences's cash & equivalents?
Gilead Sciences (GILD) reported cash & equivalents of $7.63B in Q1 2026.
How has Gilead Sciences's cash & equivalents changed year-over-year?
Gilead Sciences's cash & equivalents decreased by 3.8% year-over-year, from $7.93B to $7.63B.
What is the long-term trend for Gilead Sciences's cash & equivalents?
Over 5 years (2020 to 2025), Gilead Sciences's cash & equivalents has grown at a 4.8% compound annual growth rate (CAGR), from $6B to $7.56B.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.